Revenue decreased by 4.9% to $527,478 for the three months ended September 30, 2024 compared to revenue for the three months ended September 30, 2023. Elevai’s Chief Executive Officer and Chief Financial Officer, Graydon Bensler, stated: “Our third fiscal quarter was a period of meaningful and strategic progress for Elevai Labs (ELAB) and our subsidiaries, Elevai Skincare, Elevai Biosciences and Elevai Research. In this fiscal quarter we also strengthened our financial position with the successful completion of an $8 million public offering. We’re excited to continue building on this momentum as we head into the next fiscal quarter. We remain committed to identifying ways to drive value for both our customers and shareholders and are actively exploring strategic, value-driven acquisitions and potential spin out opportunities that we believe will create shareholder value.”
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAB:
- Biotech Alert: Searches spiking for these stocks today
- Elevai Biosciences engages KCRN Research to support IND efforts for EL-22
- Elevai Biosciences highlights past preclinical data on EL-32
- Elevai Labs files two patent applications for EL-22 in muscle loss
- Elevai Labs begins clinical study of topical exosome product